Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR +/ HER2 ‐Negative Breast Cancer: A Real‐World Study
Authors:
- Maurício Fernando Silva Almeida RibeiroMRMaurício Fernando Silva Almeida Ribeiro
- Rudinei Diogo Marques LinckRLRudinei Diogo Marques Linck
- Isabela Flauzino FerreiraIFIsabela Flauzino Ferreira
- Cibele MasottiCMCibele Masotti
- Rodrigo SaddiRSRodrigo Saddi
- Karina Perez SacardoKSKarina Perez Sacardo
- Leandro Jonata Carvalho OliveiraLOLeandro Jonata Carvalho Oliveira
- Daniele Coelho DuarteDDDaniele Coelho Duarte
- Paula Fontes AsprinoPAPaula Fontes Asprino
Open Access
- 1 October 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72208
Abstract
Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and breast cancer (MBC). This real‐world, longitudinal study included 48 metastatic patients (42 with EGFR ‐mutant NSCLC; 6 with HR+/HER2‐negative MBC) treated at a Brazilian oncology reference center. Serial plasma samples were analyzed by ddPCR for activating and resistance mutations at specific time points. In the NSCLC cohort, EGFR T790M was detected in 48.4% of patients who progressed on 1st/2nd‐generation TKIs. For patients on 3rd‐generation TKIs, EGFR C797S was the main AR mechanism (47%), followed by PIK3CA , BRAF mutations, and ERBB2 / EGFR amplifications. Longitudinal analysis anticipated radiological progression by approximately 5 months. Early molecular response, characterized by mutation clearance, preceded radiological response. In the MBC cohort, hotspot ESR1 mutations (D538G, L536R, Y537S) were identified in 50% of patients. Variations in ctDNA fractional abundance predicted disease progression up to 9 months before radiological confirmation. This study provides real‐world evidence that ddPCR‐based ctDNA monitoring enables early detection of resistance and predicts disease progression significantly earlier than standard imaging in both NSCLC and MBC. Despite the limited sample size, particularly in the MBC cohort, these real‐world findings support liquid biopsy as a minimally invasive tool with the potential to guide therapeutic decisions and inform personalized management in precision oncology. Larger prospective studies are needed to confirm these observations.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2015/16854‐4)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2016/05375‐0)
- Virginia and D.K. Ludwig Fund for Cancer Research
This publication has 47 references indexed in Scilit:
- Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysisCancer Treatment and Research Communications, 2025
- Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3Journal of Thoracic Oncology, 2024
- Liquid biopsy into the clinics: Current evidence and future perspectivesThe Journal of Liquid Biopsy, 2024
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerJournal of Thoracic Oncology, 2021
- Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLCLung Cancer, 2017
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast CancerJAMA Oncology, 2016
- First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain MetastasesJournal of Thoracic Oncology, 2016
- Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinibCancer, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009